Thomas Catinazzo - Mar 30, 2021 Form 4/A - Amendment Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: Senior Vice President, Finance
Signature: /s/ Brian Adams, as Attorney-in-Fact
Stock symbol: RLAY
Transactions as of: Mar 30, 2021
Transactions value $: -$694,800
Form type: 4/A - Amendment
Date filed: 6/9/2021, 08:33 PM
Date Of Original Report: Apr 1, 2021
Next filing: Jun 9, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Options Exercise	$92.7K	+22.5K	+141.78%	$4.12	38.4K	Mar 30, 2021	Direct	F1
transaction	RLAY	Common Stock	Sale	-$788K	-22.5K	-58.64%	$35.00	15.9K	Mar 30, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLAY	Stock Option (Right to Buy)	Options Exercise	$0	-22.5K	-17.37%	$0.00	107K	Mar 30, 2021	Common Stock	22.5K	$4.12	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020.
F2	Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Remarks:

The Form 4 filed on April 1, 2020 by the reporting person inadvertently understated the number of shares beneficially owned following the reported transactions by 15,870 shares in Column 5 of Table I.